GCNT2
Basic information
Region (hg38): 6:10492223-10629368
Previous symbols: [ "NACGT1", "II", "GCNT5", "CCAT" ]
Links
Phenotypes
GenCC
Source:
- cataract 13 with adult I phenotype (Moderate), mode of inheritance: AR
- total early-onset cataract (Supportive), mode of inheritance: AD
- cataract 13 with adult I phenotype (Definitive), mode of inheritance: AR
- cataract 13 with adult I phenotype (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Blood group, Ii; Adult i phenotype without cataract | BG/AR | Hematologic | Variants associated with a blood group may be important in specific situations (eg, related to transfusion) | Hematologic; Ophthalmologic | 6858080; 3799539; 11739194; 12424189; 21912254 |
ClinVar
This is a list of variants' phenotypes submitted to
- Cataract 13 with adult I phenotype (5 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the GCNT2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 17 | |||||
missense | 32 | 41 | ||||
nonsense | 4 | |||||
start loss | 0 | |||||
frameshift | 6 | |||||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 48 | 16 | 30 | 94 | ||
Total | 5 | 1 | 89 | 28 | 40 |
Highest pathogenic variant AF is 0.000315
Variants in GCNT2
This is a list of pathogenic ClinVar variants found in the GCNT2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
6-10509132-C-T | Uncertain significance (Oct 01, 2022) | |||
6-10528561-T-C | Benign (Jun 29, 2018) | |||
6-10528781-A-G | Benign (Oct 01, 2018) | |||
6-10528854-T-C | Benign (Oct 02, 2018) | |||
6-10528886-A-C | Benign (Jun 29, 2018) | |||
6-10528925-G-A | Cataract 13 with adult I phenotype • GCNT2-related disorder | Pathogenic (May 06, 2021) | ||
6-10529053-G-A | GCNT2-related disorder | Uncertain significance (Mar 28, 2024) | ||
6-10529216-C-G | GCNT2-related disorder | Likely benign (Apr 09, 2019) | ||
6-10529258-C-T | Inborn genetic diseases | Uncertain significance (Nov 09, 2021) | ||
6-10529336-A-T | Inborn genetic diseases | Uncertain significance (Jul 09, 2021) | ||
6-10529416-G-A | ADULT i BLOOD GROUP PHENOTYPE | Pathogenic (Mar 15, 2003) | ||
6-10529469-T-G | Cataract 13 with adult I phenotype | Uncertain significance (Feb 08, 2022) | ||
6-10529478-C-G | Inborn genetic diseases | Uncertain significance (Aug 23, 2021) | ||
6-10529528-A-G | Inborn genetic diseases | Uncertain significance (Oct 12, 2021) | ||
6-10529551-A-C | Inborn genetic diseases | Uncertain significance (Sep 16, 2021) | ||
6-10529594-G-A | ADULT i BLOOD GROUP PHENOTYPE | Pathogenic (Mar 15, 2003) | ||
6-10529605-G-A | Inborn genetic diseases | Uncertain significance (Nov 05, 2021) | ||
6-10529640-C-T | GCNT2-related disorder | Likely benign (Nov 04, 2021) | ||
6-10529731-G-A | GCNT2-related disorder | Likely benign (Jul 01, 2024) | ||
6-10529757-C-T | GCNT2-related disorder | Likely benign (Sep 01, 2022) | ||
6-10529772-C-G | GCNT2-related disorder | Likely benign (May 22, 2019) | ||
6-10529773-T-C | Inborn genetic diseases | Uncertain significance (Jul 14, 2021) | ||
6-10529803-G-A | GCNT2-related disorder | Likely benign (Apr 03, 2024) | ||
6-10529940-C-A | Likely benign (Jul 31, 2018) | |||
6-10530003-A-T | Likely benign (Mar 24, 2019) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
GCNT2 | protein_coding | protein_coding | ENST00000379597 | 3 | 137146 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.0000241 | 0.761 | 125589 | 0 | 159 | 125748 | 0.000632 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -1.10 | 262 | 216 | 1.21 | 0.0000120 | 2643 |
Missense in Polyphen | 72 | 64.981 | 1.108 | 830 | ||
Synonymous | -1.28 | 105 | 89.6 | 1.17 | 0.00000578 | 783 |
Loss of Function | 1.14 | 9 | 13.5 | 0.665 | 6.53e-7 | 168 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00201 | 0.00201 |
Ashkenazi Jewish | 0.0000992 | 0.0000992 |
East Asian | 0.00261 | 0.00261 |
Finnish | 0.000277 | 0.000277 |
European (Non-Finnish) | 0.000247 | 0.000246 |
Middle Eastern | 0.00261 | 0.00261 |
South Asian | 0.00105 | 0.00105 |
Other | 0.000977 | 0.000978 |
dbNSFP
Source:
- Function
- FUNCTION: Branching enzyme that converts linear into branched poly-N-acetyllactosaminoglycans. Introduces the blood group I antigen during embryonic development. It is closely associated with the development and maturation of erythroid cells. {ECO:0000269|PubMed:7579796, ECO:0000269|PubMed:8449405}.;
- Disease
- DISEASE: Cataract 13, with adult i phenotype (CTRCT13) [MIM:116700]: An opacification of the crystalline lens of the eye that frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. In general, the more posteriorly located and dense an opacity, the greater the impact on visual function. CTRCT13 is associated with the rare adult i phenotype, in which adult red blood cells are rich in i antigen and contain low levels of I antigen. {ECO:0000269|PubMed:11739194}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Glycosphingolipid biosynthesis - lacto and neolacto series - Homo sapiens (human);Glycosphingolipid biosynthesis - neolactoseries;terminal <i>O</i>-glycans residues modification
(Consensus)
Recessive Scores
- pRec
- 0.159
Intolerance Scores
- loftool
- 0.977
- rvis_EVS
- -1.3
- rvis_percentile_EVS
- 4.95
Haploinsufficiency Scores
- pHI
- 0.213
- hipred
- N
- hipred_score
- 0.180
- ghis
- 0.464
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.414
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Gcnt2
- Phenotype
- renal/urinary system phenotype; immune system phenotype; hematopoietic system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); homeostasis/metabolism phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan);
Gene ontology
- Biological process
- glycosaminoglycan biosynthetic process;protein glycosylation;transforming growth factor beta receptor signaling pathway;multicellular organism development;positive regulation of cell population proliferation;posttranscriptional regulation of gene expression;positive regulation of epithelial to mesenchymal transition;negative regulation of cell-substrate adhesion;positive regulation of cell migration;positive regulation of heterotypic cell-cell adhesion;maintenance of lens transparency;positive regulation of protein kinase B signaling;positive regulation of ERK1 and ERK2 cascade
- Cellular component
- Golgi membrane;cellular_component;Golgi apparatus;membrane;integral component of membrane
- Molecular function
- N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity